<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007395.ref014">
 <label>14</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>George</surname>
   <given-names>LA</given-names>
  </name>, 
  <name>
   <surname>Sullivan</surname>
   <given-names>SK</given-names>
  </name>, 
  <name>
   <surname>Giermasz</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Rasko</surname>
   <given-names>JEJ</given-names>
  </name>, 
  <name>
   <surname>Samelson-Jones</surname>
   <given-names>BJ</given-names>
  </name>, 
  <name>
   <surname>Ducore</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant</article-title>. 
  <source>N Engl J Med</source>. 
  <year>2017</year>;
  <volume>377</volume>: 
  <fpage>2215</fpage>â€“
  <lpage>2227</lpage>. 
  <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1708538" xmlns:xlink="http://www.w3.org/1999/xlink">10.1056/NEJMoa1708538</ext-link>
  <?supplied-pmid 29211678?>
  <pub-id pub-id-type="pmid">29211678</pub-id>
 </mixed-citation>
</ref>
